R01CA256193

Characterization and Targeting of the Epigenetic State Underlying Uveal Melanoma Liver Metastasis

Uveal Melanoma (UM) is a highly aggressive and frequently fatal cancer of the eye. While only 2-4% of patients will have detectable metastases at diagnosis, up to 50% of patients later develop metastatic disease, overwhelmingly localized to the liver.

Gene expression profiling separates UM into two sub-groups, low-risk Class 1 UM and high-risk Class 2 UM. Almost all UMs harbor an initiating mutation in the GAQ signaling pathway, most commonly in GNAQ. Class 2 UMs harbor "progression mutations" in one of several genes that drive tumor progression, the most common being BAP1. Previous studies from our group identified biallelic inactivation of BAP1 as the strongest predictor of liver metastasis in UM. However, the cellular and molecular mechanisms underlying liver metastasis in UM remain undetermined. This gap in our knowledge limits our ability to develop effective adjuvant treatment for high-risk patients and systemic treatments for disseminated disease.

GAQ signaling activates the MAPK pathway in UM cells, and our preliminary single-cell data show that GAQ-mutant UMs are enriched for FOS/JUN transcriptional states. Loss of BAP1 function was associated with escape from senescence and a de-differentiated phenotype in UM cells that allowed their interaction with hepatic stellate cells, leading to progression of liver metastases and drug resistance. The de-differentiated state of UM cells was specifically dependent on HDAC1, with HDAC inhibition restoring the differentiated state of UM cells and increasing the efficacy of MEK inhibition in UM liver metastasis models.

The overarching goal of this grant is to define the mechanism by which mutant GAQ and BAP1 loss co-operate to drive UM liver metastasis development. In Aim 1, we will define how BAP1 loss alters the signaling, transcriptional, and epigenetic state of GAQ-mutant UM cells to allow senescence to be overcome. In Aim 2, we will address how the cellular state of GAQ-mutant/BAP1-loss UM activates hepatic stellate cells to generate a pro-survival niche in the liver through increased angiogenesis and upregulation of MAPK signaling. In Aim 3, we will explore the HDAC1 dependency of the GAQ-BAP1 loss UM cell state and will validate hits from recent CRISPR screens to identify novel therapeutic approaches to treat UM liver metastases, which we will validate in animal models.

At the completion of this study, we expect to have defined new approaches to prevent and treat UM liver metastases, which we will explore in clinical trials.

H. Lee Moffitt Cancer Center And Research Institute Hospital

TO PROVIDE FUNDAMENTAL INFORMATION ON THE CAUSE AND NATURE OF CANCER IN PEOPLE, WITH THE EXPECTATION THAT THIS WILL RESULT IN BETTER METHODS OF PREVENTION, DETECTION AND DIAGNOSIS, AND TREATMENT OF NEOPLASTIC DISEASES. CANCER BIOLOGY RESEARCH INCLUDES THE FOLLOWING RESEARCH PROGRAMS: CANCER CELL BIOLOGY, CANCER IMMUNOLOGY, HEMATOLOGY AND ETIOLOGY, DNA AND CHROMOSOMAL ABERRATIONS, TUMOR BIOLOGY AND METASTASIS, AND STRUCTURAL BIOLOGY AND MOLECULAR APPLICATIONS.

93.396 - Cancer Biology Research

National Cancer Institute (NCI) [HHS - NIH]

Tampa, Florida 336129497 United States

Single Zip Code

NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed) (PA-20-185)

Amendment Since initial award the total obligations have increased 372% from $684,278 to $3,231,041.